

Index

- acetylcarnitine, 72
- acetylcholinesterase (AChE), 12, 25, 25
 - and A β deposition, 310, 311
 - and A β fibrillogenesis, 304-306
 - and A β interaction, 299-313
 - inhibitors, 116
 - molecular changes in AD brain, 301, 302
 - neurotoxicity of AChE-A β complexes, 311, 312
 - peripheral anionic binding site, 305-307
 - quaternary structure, 302
 - sequence comparisons, 307, 308
 - sequence motifs for A β fibrillogenesis, 306-310
- acylCoA:cholesterolacyltransferase, 13
- ADAM-9, 112, 113
- ADAM-10, 109, 110
 - and cholesterol, 118
 - knockout mice, 110, 111
 - overexpression of, 111
- ADAM-17, 111, 112
- ageing
 - and cholesterol synthesis, 190
- alcohol dehydrogenase, 25
- aluminium
 - and AD, 225-231
 - and A β aggregation, 227-229
 - and A β anabolism, 226, 227
 - and A β catabolism, 229, 230
 - and A β neurotoxicity, 230, 231
 - and secretases, 227
 - in senile plaques, 226
- Alzheimer's disease (AD)
 - and AChE, 299-313
 - Alzheimer's disease (AD) (contd.)
 - ageing Tg mouse, 53-55
 - A β oligomers and fibrils, 171-174
 - A β oligomers and pathogenesis, 172
 - and A β phosphorylation, 381-398
 - and aluminium, 225-231
 - amyloid plaques in brain, 46, 47
 - and ApoE4, 255
 - and Apo ϵ 4 allele, 130, 139
 - ApoE4 as risk factor, 180
 - amyloid inhibition and β -sheet breakers, 351-361
 - APP mutations, 130
 - amyloid toxicity model, 70
 - and antioxidants, 71-74
 - antioxidant neuroprotection, 72-74
 - assessment of, 4
 - and CD-1, 391, 392
 - cerebral amyloid angiopathy, 47
 - cerebral metal accumulation, 237, 238
 - and cholesterol, 365-375
 - cholesterol as risk factor, 179-181
 - cholesterol turnover in brain, 192
 - clinical diagnosis of, 48
 - diffuse plaques, 4
 - in Down's syndrome, 8
 - early onset familial (FAD), 80
 - FAD and Swedish mutation, 81
 - and inflammation, 18
 - inherited familial & sporadic forms, 46
 - and insulin-degrading enzymes, 139
 - light microscopy of, 3-15
 - and lipid rafts, 188
 - and membrane disordering, 319-333
 - and membrane ion transport, 339-348
 - and metal chelators, 243-246
 - microglial activation, 353
 - microscopy of, 1-34
 - neuronal death, 61
 - neurodegeneration in, 80

- Alzheimer's disease (AD) (contd.)
 neurotoxicity of AchE-A β complexes, 311, 312
 neuropathological lesions in, 80
 neurofibrillary tangles, 47, 48
 non-amyloidogenic pathway, 105-120
 and NSAIDs, 73
 and oxidative stress, 11, 65-74, 150, 151
 oxidative changes in, 67-70
 protection by vitamin E, 155-157
 prophylactic treatment with statins, 374
 and protein misfolding, 282-285
 M1-receptor muscarinic agonists, 115
 and α -secretases, 113
 senile plaque-associated proteins, 12, 13
 β -sheet breaker drugs, 359, 360
 and soluble A β oligomers, 93-96
 and synaptic morphology, 16, 17
 and testosterone, 117
 TEM of 15-29
 thin section TEM of, 16-18
 transgenic models, 9-11, 45-61
 Tg mouse and clusterin, 288, 289
 and vascular pathology, 16
- amyloid- β
 affinity for lipids, 327-329
 aggregation inhibitors, 354-357
 and AD pathogenesis, 352-354
 AFM and oligomerization, 30-32
 aggregation and Congo red-binding, 213-215
 aggregation pathways, 169-171
 aluminium and aggregation, 227-229
 aluminium and catabolism, 229, 230
 aluminium and neurotoxicity, 230, 231
 annular oligomers, 20
 antibodies to, 32
 anti-oligomer antibody, 19
 ApoE-interaction, 255-267
 aspirin interaction, 28
 atomic models of, 216-219
 and BACE1 knockout, 88
 binding to CDK1, 388, 389
 Ca²⁺ ionophore formation, 344, 345
 catalase-binding, 24, 25
 cholesterol-binding, 26
 cholesterol and fibrillogenesis, 181-189
 conformational heterogeneity, 169
 Congo red-binding, 203-220
 to A β fibrils, 216
- amyloid- β (contd.)
 and α B-crystallin binding, 6, 25
 cytotoxicity and phosphorylation, 381
 degradation, 129-140
 pathway, 131, 132
 donut-like oligomers, 346, 347
 drug inhibition of fibrillogenesis, 27-29
 fibrils, 22, 23
 fibril assembly, 170, 171
 fibril-associated proteins, 23-26
 fibril polymorphism, 28
 ganglioside binding, 183-189
 α -helix content of oligomers, 19
 hydrogen peroxide release, 151
 and increase of cytosolic Ca²⁺, 342-344
 inhibition of fibrillogenesis, 17, 29
 ion channels, 20, 339-348
 intracellular A β , 368-372
 interaction with membranes, 327-329
 internalization of, 131
 intraneuronal deposition of, 17
 interaction with membrane lipids, 182
 kinetic studies, 213-215
 ligand-activated ion channels, 346
 lipid peroxidation by, 243
 localization of, 5
 long and short A β s, 130
 and membrane Ca²⁺, 332
 and membrane fluidity, 322-327
 and membrane ion transport, 339-348
 metal interaction and chelation, 235-247
 as a metalloprotein, 239, 240
 monoclonal antibodies to, 183
 nanotube β -helix model, 217-219
 neurotoxic sequence of, 322
 neurotoxicity of, 23, 70, 320, 341
 neurotoxicity of AchE-A β complexes, 311, 312
 neurotoxicity and oxidative state, 240-243
 normal function of, 95
 in Nieman Pick (NPC) brain, 194
 oligomers of, 18-20, 93-96, 170
 IDE resistance of, 136, 137
 oligomerization and fibrillogenesis, 18-29
 overproduction of, 80
 parallel β -sheet model, 219
 peptide phosphorylation, 382, 383
 phosphorylated aa residues, 382
 phosphorylation and AD, 381-398

- amyloid- β (contd.)
 - phosphorylation and aggregation, 393
 - phosphorylation by CDK-1, 389-391
 - phosphorylation and neurotoxicity, 393-395
 - physiological serine phosphorylation in AD, 382
 - polyclonal antibody to oligomers, 172, 173
 - and proteoglycans, 12
 - protofilaments, 20-22
 - scFv antibodies to, 32
 - β -sheet breakers, 357-359
 - β -sheet content of, 19, 20
 - soluble form, 284
 - and statins, 118
 - vacuolar A β , 148-150
 - variability of A β peptides, 18
 - and vascular smooth muscle cells, 149, 150
- amyloid plaque, 46, 47
 - A β 1-42 as prime cause, 56
 - accumulation of, 167, 168
 - AChE in plaques, 300, 301, 303
 - and ageing, 53-55
 - classification of, 4
 - cholesterol content, 6, 13, 14
 - degradation by IDE, 136-139
 - and ementia, 94
 - diffuse, 4, 50
 - immuno-staining of, 50
 - labelling of, 4
 - metal content, 151
 - neprilysin staining, 134
 - neuronal, 6
 - senile, 4, 50
 - TEM immunolabelling of, 18
- amyloid precursor protein (APP), 5
 - and A β 1-42 production, 81
 - and cholesterol, 118
 - degradation of mutants, 138, 139
 - and Down's syndrome, 80
 - during ageing, 53-55
 - endoproteolysis of, 80, 81
 - metal binding by, 238, 239
 - mutations of, 80, 81
 - neuronal origin of, 55-56
 - processing and neurotransmitters, 115
 - overexpression in Tg mice, 48, 49
 - in cerebrospinal fluid, 113
 - α -secretase cleavage products of, 106, 107
- amyloidoses
 - and protein misfolding, 168
- amyloidoses (Contd.)
 - common structures of, 168, 169
 - common oligomer epitopes, 173
- antibody
 - to A β , 172, 173
- anti-cholinesterase drugs, 306
- α 1-antichymotripsin, 24
- anti-inflammatory drugs, 73
- antioxidants, 28, 66, 155
 - and AD, 71-74
 - biochemical classification of, 71, 72
 - enzymes, 153-154
 - enzyme mimetics, 72
- anti-sense peptide screening, 384, 385
- apolipoprotein E (ApoE), 12, 13, 180, 193, 194, 366, 367
 - A β interaction, 255-267
 - delipidated, 257-259
 - in vivo* models, 263-267
 - isoforms of, 256
 - isoform specificity, 257-262
 - knock-in mice, 194
 - lipidated, 259, 260
- apolipoprotein J
 - see* clusterin
- apoptosis, 153, 311
- aspartic protease (BACE1 / Asp2 / memapsin2), 81
- aspirin, 28
- astrocytes, 5, 6
 - cholesterol storage by, 366
 - cholesterol-ApoE uptake, 366
- atomic force microscopy (AFM), 29-33
 - dynamic imaging by, 32
 - and A β oligomerization, 30-33
- atorvastatin, 375
- atherosclerosis, 10, 14
- BACE1
 - Active site, 92
 - APP cleavage sites, 85
 - β -secretase, 81-83
 - cloning of, 83-85
 - inhibitors of, 91, 92
 - inhibitor development, 92, 93
 - knockout mice, 87-90
 - overexpression of, 90, 91
 - transfection of, 84
 - X-ray structure, 91, 92
- BACE2, 85-87
- basement membrane, 29
- biophysical techniques, 16, 21, 23, 30, 169, 170, 213
- blood brain barrier, 17, 18,

- and statins, 372
- brain
 - cholesterol, 190-195
 - cholesterol-rich membrane domains, 327
 - membrane-A β interaction, 327-329
 - 24S-hydroxycholesterol, 192
 - MMPs, 132, 133
 - plasmin, 132
- Caenorhabditis elegans*
 - Tg model for AD, 10, 11, 16
 - calcium homeostasis and cell death, 342-344
 - calcium influx
 - and donut-like A β oligomers, 346, 347
 - cannabinoids, 396, 397
 - catalase, 24, 25
 - β -catenin, 313
 - cerebrospinal fluid (CSF)
 - amyloid peptides in, 55
 - cerebral amyloid angiopathy (CAA), 47, 51-53, 148, 256
 - pathogenesis, 55, 56
 - chelation
 - as AD therapy, 243-246
 - clinical studies, 244-246
 - cholesterol, 10
 - and AD, 366-375
 - and AD risk, 180, 181
 - and A β fibrillogenesis, 26, 179-197
 - in amyloid plaques, 13, 14
 - asymmetry in membrane bilayer, 193
 - in brain neuronal membranes, 190-195
 - degradation products, 374
 - depletion with M β CD, 330, 368
 - distribution in bilayer, 329
 - feeding, 373
 - and GA β , 185-189
 - 24S-hydroxycholesterol, 192, 193
 - increase in DS, 191, 192
 - inhibition of synthesis, 185, 186
 - intracellular, 368-372
 - and lipid rafts, 329
 - hydroxylases, 14
 - lowering drugs, 117-119
 - and membrane domains, 119
 - microcrystals, 26
 - neuronal, 180
 - in plasma membranes, 329
 - protection against A β toxicity, 330
 - and secretase activities, 370, 371
 - in senile plaques, 189
 - soluble, 26
 - cholesterol (Contd.)
 - sorting and Rab7 compartment, 370
 - turnover in brain, 366
 - cholinesterase inhibitors, 116
 - clioquinol, 74
 - cloning
 - of BACE1, 83-85
 - clusterin (ApoJ), 30
 - and AD, 273-290
 - as A β carrier, 285, 286
 - as amyloid-associated protein, 286-288
 - as a chaperone, 282
 - multifunctional protein, 280-285
 - protein conservation, 278-280
 - secreted and intracellular forms, 274-276
 - structure and expression, 274-278
 - collagen, 28, 29
 - compactin, 185, 186
 - complement C1q, 8, 12, 24
 - Congo red, 4, 10, 12, 17, 27, 50, 169, 265, 266, 313
 - A β -binding, 203-220
 - binding equilibrium, 206-208
 - binding to non-amyloid proteins, 204
 - chemistry of, 205, 206
 - mechanisms of A β binding, 204
 - molecular structure, 205, 206
 - pH titration of, 209-212
 - UV/Vis spectroscopy, 208, 209
 - Copper
 - A β -binding, 239, 240
 - in AD brain, 237
 - cyclin-dependent kinase-1
 - and A β interaction, 385-388
 - activation by A β , 392
 - and AD pathology, 391, 392
 - cyclo-oxygenase, 73
 - cystatin C, 24
 - Down's syndrome (DS), 8, 68, 69, 80, 183, 256, 352
 - and aluminium, 227
 - and BACE2 gene, 86
 - brain cholesterol in, 191, 192
 - microglial activation in, 8
 - desferrioxamine, 74, 243, 244, 246
 - desintegrin, 59
 - diphenylhexatriene, 320-323, 326, 327
 - Drosophila melanogaster*
 - Tg model for AD, 11
 - Drugs
 - β -sheet breakers, 359, 360

- drugs (contd.)
 inhibition of A β fibrillogenesis, 27-29
- ebsein, 72
- endoplasmic reticulum (ER)
 and A β 1-42 production, 372
 and cholesterol synthesis, 368, 370
- endothelin-converting enzymes, 134
- enoaparin, 10
- 17 β -estradiol, 158
- estrogen, 73
- free radicals, 67, 151
 and ageing, 68
 scavengers of, 70, 156
- fibrils, 21, 22
- ganglioside GM1
 A β -binding, 183-189
 species of, 188
- ginkgo biloba, 74
- glutathione, 154
- glycogen synthase kinase-3 β , 313
- graphite, 31, 32
- heparan sulphate, 23-27
- high density lipoprotein (HDL), 285
- HMG-CoA reductase
 inhibition of, 118
- hydrogen peroxide, 151, 153, 395
 and A β fibrillogenesis, 22
 8-hydroxyguanine, 68
- idebenon, 72
- immunochemistry, 6, 8
- insulin-degrading enzyme (IDE), 135-139
 gene deletion, 138
- inflammation
 and AD, 8, 10, 12, 24
- insulysin, 135-139
- intracellular signaling pathways, 152, 153
- iodochlorhydroxyquin, 244, 246
- iron
 in AD brain, 237
- isoprostane, 68
- knockout mice, 87-90
- laser confocal microscopy, 6
- light microscopy
 of AD, 3-15
 and Down's syndrome, 8
- light microscopy (Contd.)
- immunofluorescence, 4, 5
- immuno-histochemistry, 6-10, 50
 and oxygen stress, 11
- localization of amyloid plaque-associated proteins, 12, 13
- multiphoton microscopy, 11
- total internal reflection microscopy, 15
- of transgenic mouse AD models, 9-11
- lipids
 peroxidation of, 68
- lipid rafts, 119, 187, 188, 329, 368
- lithium, 313
- LDL-receptor related proteins, 132
- LRP-2, 285
- long term potentiation, 57
- lovastatin, 367, 368, 372
- lysosomal proteases, 132
- lysosome
 cholesterol accumulation, 194, 195
- matrix metalloproteinases, 132, 133
- melatonin, 27, 74
- membrane
 -A β interaction, 182-185
- membrane fluidity
 and acyl chain flexibility, 326
 and A β , 319-333
 definition of, 320
 fluorescence probes, 321,
 functional significance of, 331, 332
- metals
 in AD brain, 237, 238
- metal chelators
 and AD, 243-246
- metalloprotease
 α -secretase, 107
 the ADAMs, 108-113
 ADAM10, 59
- methoxy-X04, 10
- methyl- β -cyclodextrin, 118, 330, 368
- mevalonate, 367
- microglia, 5, 16-18
 activation of, 6, 12
- microscopy
 of AD, 1-34
- mild cognitive impairment, 47, 48
- mitogen-activated protein kinase-1, 388-391
- monoclonal antibody
 to A β , 183, 184
- multivesicle bodies, 5, 16, 17
- neprilysin, 7, 8, 133

- neurodegeneration
 - of cholinergic nerve terminals, 18
 - neurodegenerative disorders, 66, 67
 - neurofibrillary tangles, 47, 48, 80
 - absence in Tg mice AD models, 60
 - neuroglia
 - activation of, 312
 - neuronal death, 8
 - neuronal vesicular zinc transporter, 237
 - neurons
 - and amyloid plaque formation, 6
 - neuroreceptors, 115, 116
 - neutral endopeptidase, 133
 - nicotine, 29
 - Nieman-Pick type C disease (NPC),
 - 194, 194, 370
 - nitric oxide, 150
 - nitrotyrosine, 68
 - non-steroidal anti-inflammatory drugs (NSAIDs), 73
 - notch signalling, 109, 111
- oligomers, 18-20
- olmoucine, 396
 - CDK-1 inhibition, 394, 395
- oxidative stress, 11, 150
 - and AD, 65-74
 - intracellular signaling, 152, 153
 - and metal ions, 11
 - protection by vitamin E, 155-157
- peptide
 - degradation, 359
- phenols, 71
- phospholipid bilayer
 - A β and fluidity of, 323
- phosphoramidon, 135
- phosphorylated A β , 381-398
 - phosphorylation sites, 382
 - toxicity prevention, 396, 397
- photon emission tomography, 1, 10
- plasmin, 229, 230
- plasminogen, 132
- presenilin-1 (PS1), 58
- prion protein, 20
- protein aggregation and neurodegenerative diseases, 66
- protein oxidation, 68
- protein kinases, 381, 382
 - which kinase phosphorylates A β , 383-391
- protein kinase C, 115, 116
- protofilament, 20-22
- proteasome, 168
- reactive oxygen species, 11, 66
- reactive nitrogen species, 66
- redox metals, 240-243
- scrapie, 20
- SDS-PAGE, 18
 - of A β oligomers, 32
- α -secretases, 54, 59, 81, 105-120
 - and the ADAMs, 108
 - ADAM-9, 112, 113
 - ADAM-10, 109-111
 - ADAM-10 inhibition, 110
 - ADAM-17, 111, 112
 - and AD treatment, 114-119
 - APP cleavage site, 86
 - APPs α production, 106, 107, 113-115
 - APP products in BACE1 knockouts, 89
 - properties of, 106, 107
 - β -secretase, 81
 - functional properties of, 82, 83
 - and lipid rafts, 119
 - membrane association of, 82
 - γ -secretase, 58, 59, 81
- serum amyloid P component (SAP), 23, 24
- site-directed mutagenesis of APP, 82
- statins, 118, 181, 365-375
 - and A β levels, 118
 - and blood brain barrier, 372
 - HMG-CoA reductase inhibition, 367, 373
 - in vivo* aspects of, 372, 373
 - relevance to AD, 373-375
 - toxicity of, 372, 373
- scanning transmission electron microscopy (STEM), 23
- steroid hormones, 116, 117
- synaptosomal plasma membranes, 193, 194, 326, 328, 330, 331
 - cholesterol reduction in by statins, 373
- α -synuclein, 288
- TACE, 111, 112
- tau hyperphosphorylation, 47, 48, 381, 391, 395, 398
- testosterone
 - and AD, 117
- thioflavine, 4, 27-30, 50, 52, 53, 58, 173, 186, 228, 229, 237, 265, 266, 309
- thiorphan
 - neprilysin inhibition by, 133
- α -tocopherol (see also vitamin E), 70, 72

- transgenic models for AD, 9-11, 45-61, 69
 - value of multiple Tg mice, 60
 - A β oligomers in, 95
 - ageing and amyloid pathology, 53-55
 - ApoE-A β interaction, 265-267
 - BACE1 overexpression, 90, 91
 - BACE1^{-/-}•Tg2576, 88, 89
 - brain amyloid plaques in, 50, 51
 - cerebral amyloid angiopathy, 51-53
 - and clusterin, 288, 289
 - cognitive and behavioural defects, 57, 58
 - double Tg mice, 56
 - NEP-APP Tg, 133
 - the robust APP[V7171] model, 49-57
 - therapeutic potential of, 60
- transmission electron microscopy (TEM), 15-29
 - technical background, 15, 16
 - A β oligomerization and fibrillogenesis, 18-29
 - 3D reconstruction, 16, 18
 - drug inhibition of A β fibrillogenesis 27-29
 - transmission electron microscopy (TEM) (contd.)
 - immuno TEM, 50
 - link with LM, 16
 - STEM, 15
 - thin sectioning, 16-18
 - tumour necrosis factor- α , 111
 - vascular amyloidosis, 147, 148
 - vascular smooth muscle cells, 149, 150
 - vitamin C, 155
 - vitamin E, 70, 72, 155-157, 243
 - in vascular amyloidosis, 147-159
 - voltage gated Ca²⁺ channels, 344
- Wnt signaling pathway, 313
- X-ray computed tomography, 1, 2
- X-ray crystallography, 205, 206
- X-ray scattering, 204
- zinc
 - and A β binding, 239, 240
 - in AD brain, 237, 238
- zinc proteases
 - The ADAMs, 107-113